{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-071321","form_type":"8-K","ticker":"TSHA","cik":"0001806310","company_name":"Taysha Gene Therapies, Inc.","filed_at":"2024-03-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.606081+00:00","generated_at":"2026-06-04T13:39:13.536710+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Taysha reports 2023 net loss of $111.6M; TSHA-102 shows sustained improvements in Rett patients","bullets":["Revenue of $15.5M for full-year 2023 (up from $2.5M in 2022) from Astellas option agreement.","Net loss of $111.6M ($0.96 loss per basic share) vs. $166.0M ($3.78/share) in 2022; includes $34.5M non-cash warrant expense.","Cash and equivalents of $143.9M as of Dec 31, 2023; cash runway expected into 2026.","TSHA-102 low dose (5.7x10^14 vg) in REVEAL adult trial: well-tolerated, no SAEs; patient 1 shows improved sitting, sleep, social interaction at week 35; patient 2 shows reduced seizures at week 19.","IDMC approved early dose escalation to high dose (1x10^15 vg) in adult/pediatric trials; initial pediatric low-dose data due mid-2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-071321","json":"https://secwatch.observer/filing/0001193125-24-071321.json","markdown":"https://secwatch.observer/filing/0001193125-24-071321.md","text":"https://secwatch.observer/filing/0001193125-24-071321.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806310/000119312524071321/0001193125-24-071321-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806310/000119312524071321/d790281d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T13:39:13.536710+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bb08038cf268a6b13f4ce7d0886f8df97a1bbfcb","claim":"Taysha Gene Therapies, Inc. reported financial results for Full Year 2023.","evidence_excerpt":"On March 19, 2024, Taysha Gene Therapies, Inc. (the \" Company \") reported financial results for the year ended December 31, 2023 and recent business and clinical updates.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1806310/000119312524071321/0001193125-24-071321-index.htm","confidence":0.8,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Full Year 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}